Company intelligence / Profile preview

Tomopath

Unknown, Unknown, Unknowncdek.pharmacy.purdue.edu ↗

Ownership: Private
Development stage: Other

Overview

Tomopath is developing a diagnostic radiopharmaceutical program targeting KLK2 for the detection or management of prostatic cancer. The lead asset, 111In-DOTA-h11B6, is in preclinical development with no reported clinical results yet.

Therapeutic areas: Oncology
Modalities: Diagnostic radiopharmaceuticalsRadiolabeled antibody
Industry: Medical Imaging

Partnerships

SpectronRx (listed as sponsor/collaborator)

Beyond the preview

Go deeper on Tomopath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tomopath.

Explore the full profile